Bio-Path Holdings, Inc. (BPTH) Stock Price & Analysis
Bio-Path Holdings, Inc. (BPTH) closed at USD 0 on Friday, October 23, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 23, 2026 session ranged USD 0–0 on volume of 104 shares. Market capitalization is $15,089, with a 52-week range of USD 0–0.11 (PNK). Source: Nexqual, retrieved October 24, 2026 at 12:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BPTH.md
Key facts (BPTH)
- Analysts: None.
- Total return with dividends: 1Y -99.6% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BPTH)
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$10.9M | -$10.4M | -$13.9M | -$15.8M | -$12.0M | -$8.6M |
| Net income | -$10.9M | -$10.4M | -$13.9M | -$16.1M | -$9.9M | -$8.7M |
| EPS (diluted) | -$56.60 | -$31.00 | -$38.12 | -$33.63 | -$4.12 | — |
| Free cash flow | — | -$10.0M | -$15.1M | — | — | — |
| Cash + short-term investments | $13.8M | $23.8M | $10.4M | $1.1M | $1.2M | — |
| Total debt | $0K | $0K | $0K | $0K | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Mar 31, 2026) (BPTH)
Earnings yield -57624.76%
Analysts (BPTH)
Consensus None.
Total return (dividends reinvested) (BPTH)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -99.6% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -99.7% | -92.1% |
| Volatility (annualized) | 739.4% | 298.9% |
| Max drawdown | -99.9% (Oct 2025→Sep 2026) | -100.0% (Oct 2021→Sep 2026) |
BPTH suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Roth Capital Partners | “On August 3, 2023, we entered into a placement agency agreement with Roth Capital Partners, LLC relating to a best efforts public offering of an aggregate of 175,000 shares of its common stock, together with warrants to purchase up to 175,000 shares of its common stock (the "2023 Warrants"), for gross proceeds of approximately $2.1 million (the "2023 Public Offering").” |
| Partner | Diagonal Lending | “On March 6, 2025, we entered into a securities purchase agreement with 1800 Diagonal Lending LLC, a Virginia limited liability company (the "Lender"), an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $161,000 (the "Promissory Note") for a purchase price of $140,000 after deducting the original issue discount of $21,000.” |
Quoted from the company's 10-K filed Mar 27, 2025.
BPTH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Dec 2025) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2025) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:40 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.11 |
| Volume | 104 shares |
| Market Cap | $15,089 |
| Exchange | PNK |
Technical Analysis (BPTH)
Nexqual's technical model rates BPTH "NEUTRAL" based on 3 bullish and 4 bearish signals across 93 daily candles, as of October 24, 2026 at 12:40 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 5.22 (oversold) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (BPTH)
Wall Street analysts rate BPTH "None", per Nexqual as of October 24, 2026 at 12:40 UTC.
| Consensus Rating | None |
|---|
Earnings (BPTH)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -0.55 vs est -0.4 ▼ miss |
| 2025-03-31 | USD -0.4 vs est -0.38 ▼ miss |
| 2024-12-31 | USD -0.07 vs est -0.37 ▲ beat |
| 2024-09-30 | USD -0.7 vs est -1.02 ▲ beat |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financials & Fundamentals (BPTH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0 |
| Total Cash | $2,000 |
| Total Debt | $520,000 |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financial Health Score (BPTH)
Nexqual rates Bio-Path Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 12:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $2K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M (FY ended Dec 2024, 10-K) |
| Efficiency | Mixed — No data |
Ownership (BPTH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.87% |
| Shares Outstanding | 50.30M |
| Float | 50.30M |
| Short % of Float | +8.03% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Leadership (BPTH)
Bio-Path Holdings, Inc. is led by Vikram Paul Grover C.F.A., President, CEO, CFO & Director, per Nexqual as of October 24, 2026 at 12:40 UTC.
| President, CEO, CFO & Director | Vikram Paul Grover C.F.A. |
|---|---|
| Co-Founder, Director of Investor Relations & Secretary | Douglas P. Morris |
| Senior Vice President of Finance, Accounting & Administration | Anthony Price |
| Senior Vice President of Research, Development & Clinical Design | Ana Tari Ashizawa |
Major Backers & Investors (BPTH)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.16% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
From Bio-Path Holdings, Inc.'s Latest SEC 10-K Filing (filed 2025-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators, sponsored researchers and other advisors.
- We have developed DNAbilize® nanoparticle drug delivery systems to deliver short strands of antisense DNA drugs to cells and block the production of proteins associated with disease progression.
- Because of our unique ability to address unmet needs in hematological malignancies, our lead drug candidates focus on cancers of the blood and lymph.
- We rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable.
Partnerships
- We expect that these efforts will include collaboration with key scientific opinion leaders in the field of study and include developing drug candidates for diseases other than cancer.
- Using DNAbilize® technology, we plan to develop therapeutics to a wide range of diseases and disorders independently and in partnership with others.
Legal & Regulatory Risks (Item 1A, quoted)
- Our employees, agents, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with applicable regulatory standards and requirements.
- Our business has a substantial risk of product liability claims. If we are unable to obtain or maintain appropriate levels of insurance, a product liability claim could adversely affect our business.
- We may be subject, directly or indirectly, to certain U.S. federal and state healthcare laws and regulations, such as anti-kickback, false claims laws, physician payment transparency laws or similar fraud and abuse laws, which could expose us to potential criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Changes in existing laws and regulations affecting the healthcare industry could increase our costs and otherwise adversely affect our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt